Brain levels of dextromethorphan and the intensity of opioid withdrawal in mice

Drug and Alcohol Dependence

Volumn 95, Issue 1-2, 2008, Pages 147-151

  Bisaga, Adam ^a   Kos, Tomasz ^b   Wójcikowski, Jacek ^b   Daniel, Wladyslawa Anna ^b   Popik, Piotr ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Dextromethorphan; Dextrorphan; Mice; Opioid withdrawal; Quinidine

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN; GLUTAMATE RECEPTOR; GLYCOPROTEIN P; MORPHINE; NALOXONE; OPIATE DERIVATIVE; QUINIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG EFFECT; MALE; MOUSE; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; WITHDRAWAL SYNDROME;

ANIMALS; BRAIN; DEXTROMETHORPHAN; DEXTRORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; MASTICATION; MICE; MICE, INBRED C57BL; MORPHINE; MORPHINE DEPENDENCE; MOTOR ACTIVITY; NALOXONE; NARCOTIC ANTAGONISTS; QUINIDINE; STEREOTYPED BEHAVIOR; SUBSTANCE WITHDRAWAL SYNDROME;

MUS;

EID: 40649083869     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.01.007     Document Type: Article

References (31)

1. Akerele E., Bisaga A., Nunes E.V., Sullivan M.A., Garawi F., Comer S.D., Thomas A.A., Nunes E.V., and Kleber H.D. Dextromethorphan/Quinidine for opioid Detoxification. Am. J. Addictions 17 3 (2008)
2. Albers G.W., Saenz R.E., and Moses J.A. Tolerability of oral dextromethorphan in patients with a history of brain ischemia. Clin. Neuropharmacol. 15 (1992) 509-514
3. Bem J.L., and Peck R. Dextromethorphan: an overview of safety issues. Drug Saf. 7 (1992) 190-199
4. Bertilsson L., Dahl M.L., Dalen P., and Al Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 53 (2002) 111-122
5. Bisaga A., and Popik P. In search of a new pharmacological treatment of drug addiction: N-methyl-d-aspartate (NMDA) antagonists. Drug Alcohol Depend. 59 (2000) 1-15
6. Bisaga A., Gianelli P., and Popik P. Opiate withdrawal using dextromethorphan. Am. J. Psychiatry 154 (1997) 584
7. Bolden R.D., Hoke S.H., Eichhold T.H., McCauley-Myers D.L., and Wehmeyer K.R. Semi-automated liquid-liquid back-extraction in a 96-well format to decrease sample preparation time for the determination of dextromethorphan and dextrorphan in human plasma. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 772 (2002) 1-10
8. Capon D.A., Bochner F., Kerry N., Mikus G., Danz C., and Somogyi A.A. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin. Pharmacol. Ther. 60 (1996) 295-307
9. Chauret N., Gauthier A., Martin J., and Nicoll-Griffith D.A. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab. Dispos. 25 (1997) 1130-1136
10. Dematteis M., Lallement G., and Mallaret M. Dextromethorphan and dextrorphan in rats: common antitussives-different behavioural profiles. Fundam. Clin. Pharmacol. 12 (1998) 526-537
11. Farzin D. Modification of naloxone-induced withdrawal signs by dextromethorphan in morphine-dependent mice. Eur. J. Pharmacol. 377 (1999) 35-42
12. Isbell H., and Fraser H.F. Actions and addiction liabilities of dromoran derivatives in man. J. Pharmacol. Exp. Ther. 107 (1953) 524-530
13. Koyuncuoglu H. The treatment with dextromethorphan of heroin addicts on ambulatory basis. In: Loimer N., Schmid R., and Springer A. (Eds). The Abstracts Band of the First European Symposium on Drug Addiction and AIDS (1991), Springer Verlag, Vienna, Austria 320-329
14. Koyuncuoglu H. The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients. Int. J. Clin. Pharmacol. Ther. 33 (1995) 13-19
15. Koyuncuoglu H., and Saydam B. The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chloropromazine. Int. J. Clin. Pharmacol. Ther. 28 (1990) 147-152
16. Koyuncuoglu H., Gungor M., Sagduyu H., and Ariciogly F. Suppression by ketamine and dextromethorphan of precipitated abstinence syndrome in rats. Physiol. Behav. 35 (1990) 829-832
17. Kozela E., Wrobel M., Kos T., Wojcikowski J., Daniel W.A., Wozniak K., Slusher B.S., and Popik P. 2-MPPA, a selective glutamate synthesis inhibitor, inhibits morphine tolerance but not dependence in C57/Bl mice. Psychopharmacology 183 (2005) 275-284
18. Lee G., Dallas S., Hong M., and Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53 (2001) 569-596
19. Lin T., Pan K., Mordenti J., and Pan L. In vitro assessment of cytochrome P450 inhibition: strategies for increasing LC/MS-based assay throughput using a one-point IC(50) method and multiplexing high-performance liquid chromatography. J. Pharm. Sci. 96 (2007) 2485-2493
20. Manning B.H., Mao J.R., Frenk H., Price D.D., and Mayer D.J. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain 67 (1996) 79-88
21. Marier J.F., Pope L.E., Yakatan G.J., Berg J.E., Stiles M., and Vachon P. Influence of concomitant quinidine administration on dextromethorphan disposition in rats. J. Vet. Pharmacol. Ther. 27 (2004) 111-114
22. Marier J.F., Deschenes J.L., Hage A., Seliniotakis E., Gritsas A., Flarakos T., Beaudry F., and Vachon P. Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil. Life Sci. 77 (2005) 2911-2926
23. Marzolini C., Paus E., Buclin T., and Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75 (2004) 13-33
24. Masubuchi Y., Iwasa T., Hosokawa S., Suzuki T., Horie T., Imaoka S., Funae Y., and Narimatsu S. Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes. J. Pharmacol. Exp. Ther. 282 (1997) 1435-1441
25. Miller S.C. Dextromethorphan psychosis, dependence and physical withdrawal. Addict. Biol. 10 (2005) 325-327
26. Parsons C.G., Quack G., Bresink I., Baran L., Przegalinski E., Kostowski W., Krzascik P., Hartmann S., and Danysz W. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34 (1995) 1239-1258
27. Pope L.E., Khalil M.H., Berg J.E., Stiles M., Yakatan G.J., and Sellers E.M. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J. Clin. Pharmacol. 44 (2004) 1132-1142
28. Rosen M.I., Mcmahon T.J., Woods S.W., Pearsall H.R., and Kosten T.R. A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. Eur. J. Pharmacol. 307 (1996) 251-257
29. Schadel M., Wu D., Otton S.V., Kalow W., and Sellers E.M. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J. Clin. Psychopharmacol. 15 (1995) 263-269
30. Uhr M., Namendorf C., Grauer M.T., Rosenhagen M., and Ebinger M. P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6. J. Psychopharmacol. 18 (2004) 509-515
31. Yu A.M., and Haining R.L. Expression, purification, and characterization of mouse CYP2d22. Drug Metab. Dispos. 34 (2006) 1167-1174